Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert P Wise

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Pharmacoepidemiology and Drug Safety|May 10, 2002
Precautions for proactive surveillanceAlexander M Walker, Robert P Wise
Journal of Vascular Surgery|May 9, 2006
Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004Craig E Zinderman, Laurence Landow, Robert P Wise
The New England Journal of Medicine|February 4, 2005
Epoetin and pure red-cell aplasiaM M Braun, Robert P Wise, Jennifer J Wood
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 9, 2009
Fatality despite appropriate treatment for babesiosisDiane M Gubernot, Robert P Wise, Stanley M Spinola
BMJ Open|July 19, 2017
Incidence of live-attenuated influenza vaccine administration beyond expiry date in children and adolescents aged 2-17 years in the UK: a population-based cohort studyHerve Caspard, Robert P Wise, Amy Steffey, et al.
Nursing Outlook|June 5, 2017
Nurses leading change to advance healthPatricia Polansky, Mary Sue Gorski, Alexia Green, et al.
The Journal of Rheumatology|November 2, 2004
Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitisElizabeth M Begier, Carol A Langford, Michael C Sneller, et al.
Cell and Tissue Banking|April 12, 2011
Reported infections after human tissue transplantation before and after new Food and Drug Administration (FDA) regulations, United States, 2001 through June, 2010Tarun K Mallick, Alexis Mosquera, Craig E Zinderman, et al.
Cell and Tissue Banking|May 3, 2007
Clarification of FDA and The Joint Commission reporting requirements for US tissue recipient adverse reactionsTina Khoie, Craig E Zinderman, Ruth Solomon, et al.
JAMA|January 19, 2006
Thromboembolic adverse events after use of recombinant human coagulation factor VIIaKathryn A O'Connell, Jennifer J Wood, Robert P Wise, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Pharmacoepidemiology and Drug Safety|May 10, 2002
Precautions for proactive surveillanceAlexander M Walker, Robert P Wise
Journal of Vascular Surgery|May 9, 2006
Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004Craig E Zinderman, Laurence Landow, Robert P Wise
The New England Journal of Medicine|February 4, 2005
Epoetin and pure red-cell aplasiaM M Braun, Robert P Wise, Jennifer J Wood
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 9, 2009
Fatality despite appropriate treatment for babesiosisDiane M Gubernot, Robert P Wise, Stanley M Spinola
BMJ Open|July 19, 2017
Incidence of live-attenuated influenza vaccine administration beyond expiry date in children and adolescents aged 2-17 years in the UK: a population-based cohort studyHerve Caspard, Robert P Wise, Amy Steffey, et al.
Nursing Outlook|June 5, 2017
Nurses leading change to advance healthPatricia Polansky, Mary Sue Gorski, Alexia Green, et al.
The Journal of Rheumatology|November 2, 2004
Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitisElizabeth M Begier, Carol A Langford, Michael C Sneller, et al.
Cell and Tissue Banking|April 12, 2011
Reported infections after human tissue transplantation before and after new Food and Drug Administration (FDA) regulations, United States, 2001 through June, 2010Tarun K Mallick, Alexis Mosquera, Craig E Zinderman, et al.
Cell and Tissue Banking|May 3, 2007
Clarification of FDA and The Joint Commission reporting requirements for US tissue recipient adverse reactionsTina Khoie, Craig E Zinderman, Ruth Solomon, et al.
JAMA|January 19, 2006
Thromboembolic adverse events after use of recombinant human coagulation factor VIIaKathryn A O'Connell, Jennifer J Wood, Robert P Wise, et al.
Pageof 3